Emerging pulsed field ablation systems had their moments in the spotlight at the annual meeting of the Heart Rhythm Society ...

Of those, 141 patients also received cavotricuspid isthmus ablation with the Farapoint PFA catheter to treat atrial flutter.

Boston Scientific reports positive outcomes from the ADVANTAGE AF trial’s second phase, assessing the Farapulse and Farapoint ...

MARLBOROUGH, Mass. and SAN DIEGO, April 24, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month primary endpoint results from the second phase of the ...

Boston Scientific (NYSE: BSX) today announced positive 12-month study results for its Farapulse pulsed field ablation (PFA) ...

With careful consideration of several factors, many patients can avoid an overnight stay, reducing costs without sacrificing ...

as well as the FARAPOINT PFA Catheter for cavotricuspid isthmus ablation in treating atrial flutter. The study reported 73.4% of patients were free from AF, atrial flutter, and atrial tachycardia ...

Boston Scientific has reported positive 12-month primary endpoint outcomes from the ADVANTAGE AF trial’s second phase, assessing the Farapulse pulsed field ablation (PFA) system and Farapoint ...